At Bilim Pharmaceuticals, we have established ourselves as a market leader in the retinoid sector, boasting a comprehensive portfolio that encompasses all key active ingredients such as Tretinoin, Etretinate, Fenretinide, Isotretinoin, Alitretinoin, Tazarotene, Acitretin, and Trifarotene. Our commitment to innovation extends to the respiratory sector, where we have significantly enhanced our offering of active ingredients. This expansion is driven by our dedication to addressing unmet needs in niche therapeutic areas and our development of molecules with specialized physical properties for use in state-of-the-art inhalers.
In line with recent advancements, we have introduced several novel New Chemical Entities (NCEs) utilizing proprietary technologies and backed by patent filings. Our facilities are fully licensed for the commercial importation and processing of narcotic raw materials, enabling us to manufacture and globally distribute a range of controlled substances, including psychotropics and intermediate lysergic acid. We currently hold licenses for Schedule III and IV APIs, including Diethylpropion HCl, Phendimetrazine Tartrate, Phentermine HCl, and Benzphetamine HCl.
Looking forward, Bilim Pharmaceuticals is set to delve into Antibody-Drug Conjugates (ADCs), representing a significant frontier in the generic pharmaceutical market. This move is expected to substantially elevate our complexity and expertise. Our strategic focus on enhancing our generic drug pipeline is aligned with our commitment to the sustainability of global healthcare systems, ensuring the introduction and affordability of essential therapies worldwide.
